Company intelligence / Profile preview

PreCerv

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

NCP-01 demonstrated homing and engraftment at stroke sites in preclinical models; Hemostemix, the parent, has published safety and efficacy of ACP-01 for other ischemic conditions, but no clinical results yet specific for PreCerv.

Therapeutic areas: NeurologyOphthalmology
Modalities: Cell therapyAutologous stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on PreCerv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PreCerv.

Explore the full profile